Valuation: Isofol Medical AB

Market Cap 225M 23.23M 20.4M 18.97M 17.41M 32.71M 2.24B 33.22M 88.02M 1.1B 87.2M 85.32M 3.8B P/E 2026 *
-3.7x
P/E 2027 * -23.4x
Enterprise Value 123M 12.71M 11.17M 10.38M 9.53M 17.9M 1.22B 18.18M 48.17M 602M 47.72M 46.7M 2.08B EV / Sales 2026 *
-
EV / Sales 2027 * 3.1x
Free-Float
90.89%
Yield 2026 *
-
Yield 2027 * -
1 day-2.90%
1 week-3.70%
Current month-4.48%
1 month+0.29%
3 months+1.15%
6 months-0.71%
Current year-3.57%
1 week 0.69
Extreme 0.692
0.8
1 month 0.68
Extreme 0.685
0.95
Current year 0.55
Extreme 0.5515
0.99
1 year 0.55
Extreme 0.5515
0.99
3 years 0.45
Extreme 0.45
4.88
5 years 0.45
Extreme 0.45
14.44
10 years 0.45
Extreme 0.45
33.5
Manager TitleAgeSince
Chief Executive Officer 74 2024-01-08
Director of Finance/CFO 60 2024-08-12
Chief Executive Officer 61 2023-06-21
Director TitleAgeSince
Chairman 85 2010-06-30
Director/Board Member 76 2017-12-31
Director/Board Member 78 2024-01-03
Date Insider Type Main position Quantity % Market Cap.
12/10/21 Sell 58,767 0.0364%
12/10/21 Sell 58,767 0.0364%
6/14/21
Healthcom GmbH
BuyCompany 233,336 0.2239%
Change 5-day change 1-year change 3-year change Capi.($)
-2.90%-3.70%-27.15%+14.68% 23.23M
+0.45%+2.80%+55.83%+20.48% 324B
-0.07%+2.09%+22.76%-11.68% 68.88B
+1.35%+5.29%+39.41%+91.60% 9.72B
+0.93%-1.38%+1.71%-4.10% 8.37B
+1.13%+1.51%-20.98%-4.73% 4.32B
-4.00%+0.71%-7.10%+12.39% 3.62B
+4.90%+5.79%-39.25%+19.34% 3.83B
-2.10%-3.83%+40.64%+53.74% 2.68B
-4.07%-2.45%-3.76%-17.52% 2.04B
Average -0.44%+0.74%+6.21%+17.42% 42.72B
Weighted average by Cap. +0.37%+2.17%+46.52%+16.12%

Financials

2026 *2027 *
Net sales - 43.33M 4.47M 3.92M 3.65M 3.35M 6.29M 430M 6.39M 16.93M 212M 16.77M 16.41M 731M
Net income -61.25M -6.31M -5.55M -5.16M -4.73M -8.89M -608M -9.03M -23.93M -299M -23.71M -23.2M -1.03B -40.15M -4.14M -3.64M -3.38M -3.1M -5.83M -399M -5.92M -15.69M -196M -15.54M -15.2M -678M
Net Debt -102M -10.52M -9.24M -8.59M -7.88M -14.81M -1.01B -15.04M -39.85M -498M -39.48M -38.63M -1.72B -91M -9.38M -8.24M -7.66M -7.03M -13.21M -904M -13.42M -35.55M -444M -35.22M -34.46M -1.54B
Logo Isofol Medical AB
Isofol Medical AB is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Employees
6
Date Price Change Volume
26-07-24 SEK 0.7030 -2.90% 972,348
26-07-23 SEK 0.7240 -2.03% 394,577
26-07-22 SEK 0.7390 -0.27% 362,240
26-07-21 SEK 0.7410 +1.37% 316,777
26-07-20 SEK 0.7310 +0.14% 313,329
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISOFOL Stock